Dr. Ritesh Parajuli, MD
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Area of expertise
Breast Cancer
Ritesh Parajuli, MD has run 14 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Ritesh Parajuli, MD has run 11 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
UC Irvine Health/Chao Family Comprehensive Cancer Center
UCI Health - Chao Family Comprehensive Cancer Center And Ambulatory Care
Clinical Trials Ritesh Parajuli, MD is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
ASTX727 + Paclitaxel + Pembrolizumab
for Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ASTX727 when given in combination with a usual approach of treatment with paclitaxel and pembrolizumab in patients with triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). The usual approach is defined as care most people get for this type of cancer. The usual approach for patients with metastatic triple negative breast cancer who are not in a study is chemotherapy with drugs like paclitaxel, carboplatin, cisplatin, eribulin, vinorelbine, capecitabine, gemcitabine, doxorubicin or cyclophosphamide. There is a protein called PD-L1 that helps regulate the body's immune system. For patients who have PD-L1+ tumors, immunotherapy (pembrolizumab) is usually added to paclitaxel or carboplatin/gemcitabine as initial treatment. For patients who have PD-L1-negative tumors, chemotherapy alone is used, without immunotherapy. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ASTX727 with usual treatment approach with paclitaxel and pembrolizumab may be able to shrink or stabilize the tumor for longer than the usual approach alone in patients with metastatic triple negative breast cancer.
Recruiting
1 award
Phase 1
23 criteria
More about Ritesh Parajuli, MD
Clinical Trial Related
8 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Ritesh Parajuli, MD has experience with
- Pembrolizumab
- Paclitaxel
- Tucatinib
- Trastuzumab
- Pertuzumab
- Abemaciclib
Breakdown of trials Ritesh Parajuli, MD has run
Breast Cancer
Breast cancer
Cancer
Endometrial Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ritesh Parajuli, MD specialize in?
Ritesh Parajuli, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Ritesh Parajuli, MD currently recruiting for clinical trials?
Yes, Ritesh Parajuli, MD is currently recruiting for 6 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Ritesh Parajuli, MD has studied deeply?
Yes, Ritesh Parajuli, MD has studied treatments such as Pembrolizumab, Paclitaxel, Tucatinib.
What is the best way to schedule an appointment with Ritesh Parajuli, MD?
Apply for one of the trials that Ritesh Parajuli, MD is conducting.
What is the office address of Ritesh Parajuli, MD?
The office of Ritesh Parajuli, MD is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.